IMMUNE CHECKPOINT INHIBITORS AVAILABLE IN PHARMACOTHERAPY AND THEIR IMMUNE RELATED ADVERSE EFFECTS

• At: AbuDhabi (United Arab Emirates) (2019)
• Type: Poster
• Poster code: POS-HPS-107
• By: MORGADO, Manuel (University of Beira Interior, Health Science Faculty, Portugal)
• Co-author(s): Manuel Morgado: Pharmaceutical Services, University Hospital Center of Cova da Beira, Covilhã, Portugal;Health Science Faculty, University of Beira Interior, Covilhã, Portugal
  Sandra Morgado: Pharmaceutical Services, University Hospital Center of Cova da Beira, Covilhã, Portugal
  Andreia Gaspar: Pharmaceutical Services, University Hospital Center of Cova da Beira, Covilhã, Portugal
  Ema Paulino: Portuguese Pharmaceutical Society, Lisbon, Portugal
  Olímpia Fonseca: Pharmaceutical Services, University Hospital Center of Cova da Beira, Covilhã, Portugal;Health Science Faculty, University of Beira Interior, Covilhã, Portugal
  
• Abstract:

  Background

  The immune checkpoint inhibitors (ICPI) have revolutionized the treatment of various oncological pathologies. These drugs target the signaling pathways of the immune system, contributing to restore immune responses against cancer cells. However, stimulation of the immune system can lead to overactivation of T-lymphocytes, causing

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login